Jazz Pharmaceuticals, Inc. - JAZZ STOCK NEWS

Jazz Pharmaceuticals has successfully completed its acquisition of GW Pharmaceuticals, enhancing its portfolio with cannabinoid-based medicines, including Epidiolex, which had over $500 million in sales in 2020. The deal is expected to accelerate top-line revenue growth and add substantial value for shareholders. The combined entity will address significant unmet medical needs in neuroscience and oncology. Jazz anticipates providing 2021 financial guidance for the integrated organization shortly.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will present a company overview and financial updates at three virtual investor conferences in May 2021. The events include the BofA Securities Health Care Conference on May 11 at 1:15 p.m. ET, the RBC Capital Markets Global Healthcare Conference on May 18 at 10:40 a.m. ET, and the UBS Global Healthcare Virtual Conference on May 24 at 11:00 a.m. ET. Interested parties can access the live webcasts on Jazz Pharmaceuticals' website, with replays available for at least a week.

Jazz focuses on developing medicines for serious diseases in neuroscience and oncology.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported a strong first quarter of 2021, with total revenues of $607.6 million, a 14% increase from the same period in 2020. The company highlighted strong demand for Xywav, achieving net product sales of $75.4 million, while Zepzelca saw sales of $54.3 million. GAAP net income was $121.8 million ($2.09 per share), recovering from a net loss of $157.8 million last year. Jazz affirmed its 2021 financial guidance, projecting revenues between $2.55 billion and $2.7 billion, and emphasized its upcoming acquisition of GW Pharmaceuticals as pivotal for growth.

Jazz Pharmaceuticals has successfully closed its offering of $1.5 billion in 4.375% senior secured notes due in 2029. The proceeds will be used for the acquisition of GW Pharmaceuticals, refinancing existing debt, and related expenses. The notes will mature on January 15, 2029 and are guaranteed by the company and its subsidiaries. The offering was targeted at qualified institutional buyers and is subject to certain conditions, including the successful completion of the acquisition by August 3, 2021.

Jazz Pharmaceuticals has priced a $1.5 billion offering of 4.375% senior secured notes due January 15, 2029. The offering amount was reduced from an expected $2.7 billion, reflecting an increase in term loan borrowings for the proposed acquisition of GW Pharmaceuticals, now estimated at $3.85 billion. Proceeds will be used to fund the acquisition, refinance existing debt, and cover related expenses. The offering is not contingent on the acquisition's closure. Jazz aims to enhance growth and shareholder value through this strategic move.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced a private offering of senior secured notes to fund the proposed acquisition of GW Pharmaceuticals and refinance existing debt. The offering is not conditioned on the acquisition's closing. If the acquisition does not occur by August 3, 2021, or the transaction agreement is terminated, the notes will be redeemed at 100% of their principal plus interest. The notes will only be offered to qualified institutional buyers and are exempt from registration under the Securities Act.

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced positive results from the Phase 3 study of Xywav for treating idiopathic hypersomnia, presented at the 2021 AAN Annual Meeting. The results indicate significant improvements in the Epworth Sleepiness Scale (ESS) and Idiopathic Hypersomnia Severity Scale (IHSS) scores, showing the potential of Xywav as a treatment for this chronic sleep disorder. The FDA has accepted a supplemental New Drug Application for Xywav and granted it Priority Review.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will announce its 2021 first quarter financial results on May 4, 2021, after market close. A live audio webcast will follow at 4:30 p.m. ET for discussion of the results and business updates. Interested parties can access the webcast via the company's website. Jazz Pharmaceuticals focuses on developing medicines for serious diseases, particularly in neuroscience and oncology, serving patients in over 90 countries.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has received Priority Review designation from the FDA for its supplemental New Drug Application (sNDA) for Xywav, an oral solution aimed at treating idiopathic hypersomnia in adults. The FDA will file the sNDA on April 13, 2021, with a decision expected by August 12, 2021. The Phase 3 clinical study met its primary endpoint, showing significant improvements in patients' daytime sleepiness levels. The results will be presented at the 2021 AAN Annual Meeting on April 20, 2021.